펩티드 약물 접합체 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Peptide Drug Conjugates Market size is expected to reach USD 6.63 Billion in 2034 from USD 1.26 Billion (2025) growing at a CAGR of 20.23% during 2026-2034.

The Global Peptide Drug Conjugates Market is growing rapidly as researchers explore targeted drug delivery systems for improved therapeutic outcomes. Peptide drug conjugates combine peptides with active drug molecules to enhance precision and reduce side effects. This approach is gaining popularity in cancer treatment and other chronic diseases.

Growth drivers include rising cancer cases, increasing research in targeted therapies, and advancements in biotechnology. Pharmaceutical companies are investing heavily in developing peptide-based therapeutics due to their high specificity and better patient outcomes. Growing clinical trials and collaborations between biotech firms and research institutes are also supporting market expansion.

In the future, continued innovation in drug conjugation technologies and expanding applications beyond oncology will drive market growth. As demand for safer and more effective treatments increases, peptide drug conjugates are expected to play a key role in next-generation therapies, ensuring strong long-term prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Lutetium
• Melflufen
• ANG1005
• BT1718
• CBX-12
• Other Pipeline Products

By Type

• Therapeutic Peptide Drug Conjugates
• Diagnostic Peptide Drug Conjugates

COMPANIES PROFILED

• Novartis AG, Oncopeptides AB, Bicycle Therapeutics, AstraZeneca, Cybrexa Therapeutics, Angiochem Inc, Innovasium Soricimed Biopharma, Theratechnologies, Coherent Biopharma, WuXI STA
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Lutetium Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Melflufen Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. ANG1005 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. BT1718 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. CBX-12 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Other Pipeline Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Therapeutic Peptide Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Peptide Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PEPTIDE DRUG CONJUGATES MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Type
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Type
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Type
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Type
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Type
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PEPTIDE DRUG CONJUGATES INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Novartis AG
  • 8.2.2 Oncopeptides AB
  • 8.2.3 Bicycle Therapeutics
  • 8.2.4 AstraZeneca
  • 8.2.5 Cybrexa Therapeutics
  • 8.2.6 Angiochem Inc
  • 8.2.7 Innovasium Soricimed Biopharma
  • 8.2.8 Theratechnologies
  • 8.2.9 Coherent Biopharma
  • 8.2.10 WuXI STA